Novo Nordisk’s Sustainable Business Approach in China Cited by Michael Porter
Report on shared value released: ‘Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health’
(3BL Media) March 14, 2012 - Novo Nordisk's Triple Bottom Line business approach has caught the attention of world-renowned business strategist, Michael Porter of Harvard Business School. Last year, Novo Nordisk published 'The Blueprint for Change: Changing diabetes in China' on how strengthening of the healthcare system and establishing local stakeholder relations are key elements of Novo Nordisk's long-term business strategy for China.
Novo Nordisk is a focused healthcare company.
Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical prsion and society.
